Clinical trial · Observational
Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
NCT04737551CI-TRIAL-00049881unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective observation cohort study to evaluate efficacy of different types of adjuvant therapy strategies, including chemoradiotherapy, chemotherapy alone, or no adjuvant treatment, for pancreatic ductal adenocarcinoma patients who received surgical resection of primary cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adjuvant Chemoradiotherapy | — | UNRESOLVED | — |
| Resectable Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adjuvant chemoradiotherapy | Radiation | — | UNRESOLVED |
| Adjuvant chemoradiotherapy + Adjuvant chemotherapy | Radiation | — | UNRESOLVED |
| Adjuvant chemotherapy | Drug | Adjuvant Chemotherapy | ALIAS |
| Follow-up only | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- No adjuvant treatment
- description
- Pancreatic cancer patients who received surgery without subsequent adjuvant treatment.
- interventionNames
- Other: Follow-up only
- label
- Adjuvant chemotherapy
- description
- Pancreatic cancer patients who received surgery and only adjuvant chemotherapy.
- interventionNames
- Drug: Adjuvant chemotherapy
- label
- Adjuvant chemoradiotherapy
- description
- Pancreatic cancer patients who received surgery and only adjuvant chemoradiotherapy.
- interventionNames
- Radiation: Adjuvant chemoradiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age between 18 to 90 years. 2. Received surgical resection of primary tumor. 3. Histological diagnosis of pancreatic ductal adenocarcinoma. 4. Signed informed consent. Exclusion Criteria: 1.Active concomitant malignancy (Malignancy other than pancreatic cancer).
References
Publications (5)
- BACKGROUNDUesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016 Jul 16;388(10041):248-57. doi: 10.1016/S0140-6736(16)30583-9. Epub 2016 Jun 2. PMID 27265347
- BACKGROUNDGoodman KA, Regine WF, Dawson LA, Ben-Josef E, Haustermans K, Bosch WR, Turian J, Abrams RA. Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):901-8. doi: 10.1016/j.ijrobp.2012.01.022. Epub 2012 Apr 5. PMID 22483737
- BACKGROUNDPalta M, Godfrey D, Goodman KA, Hoffe S, Dawson LA, Dessert D, Hall WA, Herman JM, Khorana AA, Merchant N, Parekh A, Patton C, Pepek JM, Salama JK, Tuli R, Koong AC. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2019 Sep-Oct;9(5):322-332. doi: 10.1016/j.prro.2019.06.016. PMID 31474330
- BACKGROUNDMa SJ, Hermann GM, Prezzano KM, Serra LM, Iovoli AJ, Singh AK. Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer. Cancer Med. 2019 Mar;8(3):939-952. doi: 10.1002/cam4.1967. Epub 2019 Jan 16. PMID 30652417
- BACKGROUNDAbrams MJ, Huber KE, Knisely JP, Chang BW, Russo SM, Saif MW. Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study. Anticancer Res. 2015 Dec;35(12):6901-7. PMID 26637914